# US 2026/0076990 A1 · Dsrna, use thereof and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076990 A1
- Document ID: US20260076990A1
- Status: Published application
- Kind: A1
- Application number: 18/730,303
- Filed: 2023-01-19
- Published: 2026-03-19
- Earliest claimed: 2022-01-20
- Assignees: Tuojie Biotech (Shanghai) Co., Ltd.
- Applicants: Tuojie Biotech (Shanghai) Co., Ltd.
- Inventors: Yunfei Li; Yongyan Deng; Xiaoyan Lin; Yanhui Wang; Song Mao; Minyin Huang; Yaqin Zhou; Longfei Huang
- Web page: https://patentgrep.com/patent/US20260076990A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 3/06: Antihyperlipidemics
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/85: for animal cells
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/351: Conjugate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are a dsRNA, and the use thereof and a preparation method therefor. Further provided are a pharmaceutical composition, a cell or a kit containing the dsRNA. The dsRNA can interfere with the expression of APOC3, and prevent and/or treat related diseases.

## Claims

### Claim 1

A double-stranded ribonucleic acid (dsRNA) comprising a sense strand and an antisense strand that comprise contiguous nucleotides in a direction from the 5′ end to the 3′ end, wherein:
the nucleotides at positions 7, 8, and 9 of the sense strand are 2′-fluoro-modified nucleotides, the nucleotide at position 5 is independently a 2′-methoxy-modified nucleotide or 2′-fluoro-modified nucleotide, and the nucleotides at the other positions are 2′-methoxy-modified nucleotides;
the nucleotides at positions 2 and 14 of the antisense strand are 2′-fluoro-modified nucleotides, the nucleotides at positions 4, 6, 8, 9, 10, 12, 16, and 18 are independently 2′-methoxy-modified or 2′-fluoro-modified nucleotides, and the nucleotides at the other positions are 2′-methoxy-modified nucleotides;
the number of 2′-fluoro-modified nucleotides in the antisense strand is 2-7;
the antisense strand comprises a chemical modification represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof at nucleotide position 7:
the chemical modification represented by formula (I) is selected from the group consisting of any one of the following structures:
wherein B is the base of the nucleotide at position 7 of the 5′ region of the antisense strand when unmodified; and
the dsRNA inhibits the expression of apolipoprotein C3 (APOC3).

### Claim 2 (depends on 1)

The dsRNA according to claim 1, wherein:
the sense strand comprises a nucleotide sequence represented by the following formula:
5′-NaNaNaNaNaNaNbNbNbNaNaNaNaNaNaNaNaNaNa-3′;
wherein Na is a 2′-methoxy-modified nucleotide, and Nb is a 2′-fluoro-modified nucleotide; and,
wherein:
the antisense strand comprises a nucleotide sequence represented by the following formula:
5′-Na′Nb′Na′Na′Na′Nb′W′Na′Na′Na′Na′Nb′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Nb′Na′Nb′W′Na′Na′Nb′Na′Nb′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Nb′Na′Nb′W′Na′Na′Nb′Na′Na′Na′Nb′Na′Nb′Na′Nb′Na′Na′Na′-3′;
5′-Na′Nb′Na′Nb′Na′Nb′W′Na′Na′Na′Na′Nb′Na′Nb′Na′Nb′Na′Nb′Na′Na′Na′-3′;
5′-Na′Nb′Na′Na′Na′Nb′W′Na′Na′Nb′Na′Nb′Na′Nb′Na′Nb′Na′Nb′Na′Na′Na′-3′;
5′-Na′Nb′Na′Nb′Na′Nb′W′Na′Na′Na′Na′Na′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Na′Na′Nb′W′Na′Na′Nb′Na′Na′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Na′Na′Na′W′Nb′Nb′Na′Na′Na′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Na′Na′Nb′W′Na′Na′Na′Na′Na′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Na′Na′Nb′W′Na′Na′Na′Na′Na′Na′Nb′Na′Na′Na′Na′Na′Na′Na′-3′;
5′-Na′Nb′Na′Na′Na′Na′W′Na′Na′Na′Na′Na′Na′Nb′Na′Nb′Na′Na′Na′Na′Na′-3′;
or,
5′-Na′Nb′Na′Na′Na′Na′W′Na′Na′Na′Na′Na′Na′Nb′Na′Na′Na′Na′Na′Na′Na′-3′;
wherein each X′ is independently Na′ or Nb′; Na′ is a 2′-methoxy-modified nucleotide, and Nb′ is a 2′-fluoro-modified nucleotide;
W′ represents a nucleotide comprising a chemical modification represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The dsRNA according to claim 1, wherein at least one phosphoester group in the sense strand and/or the antisense strand is a phosphoester group having a modification group, preferably a phosphorothioate group, and more preferably a phosphorothioate diester group, and wherein the phosphorothioate diester group is present at at least one of the following positions:
between the first and second nucleotides of the 5′ end of the sense strand;
between the second and third nucleotides of the 5′ end of the sense strand;
between the first and second nucleotides of the 5′ end of the antisense strand;
between the second and third nucleotides of the 5′ end of the antisense strand;
between the first and second nucleotides of the 3′ end of the antisense strand; and
between the second and third nucleotides of the 3′ end of the antisense strand.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The dsRNA according to claim 1, wherein:
the sense strand comprises at least 15 contiguous nucleotides that differ from the nucleotide sequence of SEQ ID NO: 1 by no more than 3 nucleotides; and
the antisense strand comprises at least 19 contiguous nucleotides that differ from the nucleotide sequence of SEQ ID NO: 2 by no more than 3 nucleotides.

### Claim 7 (depends on 1)

The dsRNA according to claim 1, wherein:
the antisense strand comprises the nucleotide sequence set forth in any one of SEQ ID NO: 12, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 14;
and the sense strand comprises the nucleotide sequence set forth in SEQ ID NO: 3.

### Claim 8 (depends on 1)

The dsRNA according to claim 1, wherein the dsRNA further comprises a ligand conjugated thereto, and the ligand comprises N-acetylgalactosamine.

### Claim 9 (depends on 8)

The dsRNA according to claim 8, wherein:
the ligand has the following structure or a pharmaceutically acceptable salt thereof:

### Claim 10

(canceled)

### Claim 11 (depends on 8)

The dsRNA according to claim 8, wherein the ligand is linked to the 3′ end of the sense strand of the dsRNA by a phosphoester group or a phosphorothioate group, preferably by a phosphodiester group or a phosphorothioate diester group, and more preferably by a phosphodiester group.

### Claim 12 (depends on 1)

The dsRNA according to claim 1, wherein:
the antisense strand comprises the nucleotide sequence set forth in any one of SEQ ID NO: 12, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 14;
and the sense strand comprises the nucleotide sequence set forth in SEQ ID NO: 4.

### Claim 13 (depends on 1)

The dsRNA according to claim 1, wherein the dsRNA has the following structure or a pharmaceutically acceptable salt thereof:
wherein Af=adenine 2′-F ribonucleoside; Cf=cytosine 2′-F ribonucleoside; Uf=uracil 2′-F ribonucleoside; Gf=guanine 2′-F ribonucleoside; Am=adenine 2′-OMe ribonucleoside; Cm=cytosine 2′-OMe ribonucleoside; Gm=guanine 2′-OMe ribonucleoside; Um=uracil 2′-OMe ribonucleoside;
represents a phosphorothioate diester group, and
represents a phosphodiester group;
NAG0052′ represents
and
(−)hmpNA (A) represents

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the dsRNA according to claim 1, wherein optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

### Claim 15 (depends on 1)

A vector comprising the dsRNA according to claim 1.

### Claim 16 (depends on 1)

A cell comprising the dsRNA according to claim 1.

### Claim 17 (depends on 1)

Use of the dsRNA according to claim 1, wherein:
the medicament is used for lowering triglyceride levels in a subject, or for preventing and/or treating a disease mediated by elevated triglyceride levels or elevated cholesterol levels.

### Claim 18 (depends on 1)

A method for inhibiting the expression of the APOC3 gene or an mRNA thereof, comprising administering to a subject an effective amount or effective dose of the dsRNA according to claim 1.

### Claim 19 (depends on 8)

A method for delivering an oligonucleotide to a liver, comprising administering to a subject an effective amount or effective dose of the dsRNA according to claim 8.

### Claim 20 (depends on 1)

A kit comprising the dsRNA according to claim 1.

### Claim 21 (depends on 1)

A method for preparing a dsRNA or a pharmaceutical composition, comprising: synthesizing the dsRNA according to claim 1.

### Claim 22 (depends on 6)

The dsRNA according to claim 6, wherein: the sense strand comprises the nucleotide sequence set forth in SEQ ID NO: 1, and the antisense strand comprises the nucleotide sequence set forth in SEQ ID NO: 2.

### Claim 23 (depends on 17)

The use according to claim 17, wherein the disease mediated by elevated triglyceride levels or elevated cholesterol levels is selected from the group consisting of hypertriglyceridemia, obesity, hyperlipidemia, abnormal lipid and/or cholesterol metabolism, atherosclerosis, cardiovascular disease, coronary artery disease, hypertriglyceridemia-induced pancreatitis, metabolic syndrome, type II diabetes, familial chylomicronemia syndrome, and familial partial lipodystrophy.
